{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:38:40Z","timestamp":1787855920182,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Swedish Heart Association"},{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016670","name":"Region \u00d6sterg\u00f6tland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Heart, Lung and Blood Institute postdoctoral training grant","award":["T32HL094301"],"award-info":[{"award-number":["T32HL094301"]}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 HL107577"],"award-info":[{"award-number":["R01 HL107577"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 HL127028"],"award-info":[{"award-number":["R01 HL127028"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 HL140731"],"award-info":[{"award-number":["R01 HL140731"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 HL149423"],"award-info":[{"award-number":["R01 HL149423"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"British Heart Foundation Centre of Research Excellence Grant","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Compared with enalapril, sacubitril\/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial. We sought to assess the glycemic effects of sacubitril\/valsartan in heart failure with preserved ejection fraction (HFpEF) and diabetes, and across the spectrum of left ventricular ejection fraction (LVEF) in heart failure and diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We compared the effect of sacubitril\/valsartan, relative to valsartan, on HbA1c, new insulin therapy and hypoglycemia in the randomized controlled trial PARAGON-HF, and performed pooled analyses of PARAGON-HF and PARADIGM-HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 2395 patients with HFpEF and diabetes in PARAGON-HF, sacubitril\/valsartan compared with valsartan reduced HbA1c (baseline-adjusted between-group difference in HbA1c change at 48 weeks: \u2212\u20090.24%, 95% CI \u2212\u20090.33 to \u2212\u20090.16%, P\u2009&lt;\u20090.001). Numerically, new insulin treatment was initiated less often in the sacubitril\/valsartan group than in the valsartan group, but the difference was not statistically significant (12.8% vs. 16.1%; HR: 0.80, 95% CI 0.62\u20131.02, P\u2009=\u20090.07). Hypoglycemia adverse event reports were low, but more frequent in those receiving sacubitril\/valsartan than in the valsartan group (4.2% vs. 2.6%; HR: 1.64, 95% CI 1.05\u20132.56, P\u2009=\u20090.030). In a pooled analysis of PARAGON-HF and PARADIGM-HF, the effect of sacubitril\/valsartan on change in HbA1c was not significantly modified by LVEF (P<jats:sub>interaction<\/jats:sub>\u2009=\u20090.56). Across the spectrum of LVEF, sacubitril\/valsartan reduced new insulin therapy (HR: 0.75, 95% CI 0.63\u20130.89, P\u2009=\u20090.001), compared with enalapril or valsartan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Sacubitril\/valsartan reduced HbA1c and new insulin therapy in patients with heart failure and diabetes across the spectrum of LVEF but may be associated with a slightly higher risk for hypoglycemia.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>\u00a0ClinicalTrials.gov NCT01920711<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01545-1","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T11:02:38Z","timestamp":1655550158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials"],"prefix":"10.1186","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct01920711","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Magnus O.","family":"Wijkman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"R\u00f8rth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lefkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"issue":"11","key":"1545_CR1","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377\u201385.","journal-title":"Eur Heart J"},{"issue":"3","key":"1545_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","volume":"105","author":"D Aguilar","year":"2010","unstructured":"Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol. 2010;105(3):373\u20137.","journal-title":"Am J Cardiol"},{"issue":"8","key":"1545_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","volume":"135","author":"SL Kristensen","year":"2017","unstructured":"Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (irbesartan in heart failure with preserved ejection fraction). Circulation. 2017;135(8):724\u201335.","journal-title":"Circulation"},{"issue":"11","key":"1545_CR4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/hrt.2007.128769","volume":"94","author":"C Tribouilloy","year":"2008","unstructured":"Tribouilloy C, Rusinaru D, Mahjoub H, Tartiere JM, Kesri-Tartiere L, Godard S, et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart. 2008;94(11):1450\u20135.","journal-title":"Heart"},{"issue":"3","key":"1545_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ejhf.2403","volume":"24","author":"AM Jackson","year":"2022","unstructured":"Jackson AM, Rorth R, Liu J, Kristensen SL, Anand IS, Claggett BL, et al. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022;24(3):497\u2013509.","journal-title":"Eur J Heart Fail"},{"issue":"9786","key":"1545_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0140-6736(11)60471-6","volume":"378","author":"M Lind","year":"2011","unstructured":"Lind M, Bounias I, Olsson M, Gudbjornsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140\u20136.","journal-title":"Lancet"},{"issue":"11","key":"1545_CR7","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1007\/s00125-012-2681-3","volume":"55","author":"M Lind","year":"2012","unstructured":"Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjornsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012;55(11):2946\u201353.","journal-title":"Diabetologia"},{"issue":"4","key":"1545_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.amjcard.2018.11.022","volume":"123","author":"T Huynh","year":"2019","unstructured":"Huynh T, Harty BJ, Claggett B, Fleg JL, McKinlay SM, Anand IS, et al. Comparison of outcomes in patients with diabetes mellitus treated with versus without insulin + heart failure with preserved left ventricular ejection fraction (from the TOPCAT study). Am J Cardiol. 2019;123(4):611\u20137.","journal-title":"Am J Cardiol"},{"issue":"8","key":"1545_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jchf.2018.02.014","volume":"6","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan M, Claggett BL, Chatterjee NA, Anand IS, Sweitzer NK, Fang JC, et al. Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial. JACC Heart Fail. 2018;6(8):653\u201361.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"1545_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"17","key":"1545_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med"},{"issue":"5","key":"1545_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333\u201340.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1545_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cpt.455","volume":"101","author":"J Jordan","year":"2017","unstructured":"Jordan J, Stinkens R, Jax T, Engeli S, Blaak EE, May M, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther. 2017;101(2):254\u201363.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1545_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","volume":"5","author":"SD Solomon","year":"2017","unstructured":"Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017;5(7):471\u201382.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"1545_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJ McMurray","year":"2013","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062\u201373.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1545_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0009-8981(83)80002-3","volume":"127","author":"TK Mayer","year":"1983","unstructured":"Mayer TK, Freedman ZR. Protein glycosylation in diabetes mellitus: a review of laboratory measurements and of their clinical utility. Clin Chim Acta. 1983;127(2):147\u201384.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"1545_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jchf.2018.02.007","volume":"6","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau JL, Zile MR, et al. Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure. JACC Heart Fail. 2018;6(7):564\u20139.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"1545_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","volume":"8","author":"JW Cunningham","year":"2020","unstructured":"Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M, et al. Effects of sacubitril\/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(5):372\u201381.","journal-title":"JACC Heart Fail"},{"issue":"22","key":"1545_CR19","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","volume":"68","author":"MR Zile","year":"2016","unstructured":"Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68(22):2425\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1545_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352\u201361.","journal-title":"Circulation"},{"issue":"17","key":"1545_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","volume":"102","author":"PS Jhund","year":"2016","unstructured":"Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan. Heart. 2016;102(17):1342\u20137.","journal-title":"Heart"},{"issue":"10","key":"1545_CR22","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1210\/jc.2011-1182","volume":"96","author":"AM Khan","year":"2011","unstructured":"Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96(10):3242\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1545_CR23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jc.2011-2425","volume":"97","author":"M Magnusson","year":"2012","unstructured":"Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo diet and cancer study. J Clin Endocrinol Metab. 2012;97(2):638\u201345.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1545_CR24","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.2337\/db13-0478","volume":"62","author":"M Lazo","year":"2013","unstructured":"Lazo M, Young JH, Brancati FL, Coresh J, Whelton S, Ndumele CE, et al. NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62(9):3189\u201393.","journal-title":"Diabetes"},{"issue":"10","key":"1545_CR25","doi-asserted-by":"publisher","first-page":"e1001112","DOI":"10.1371\/journal.pmed.1001112","volume":"8","author":"R Pfister","year":"2011","unstructured":"Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8(10):e1001112.","journal-title":"PLoS Med"},{"issue":"11","key":"1545_CR26","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/obr.12598","volume":"18","author":"K Verboven","year":"2017","unstructured":"Verboven K, Hansen D, Jocken JWE, Blaak EE. Natriuretic peptides in the control of lipid metabolism and insulin sensitivity. Obes Rev. 2017;18(11):1243\u201359.","journal-title":"Obes Rev"},{"issue":"5","key":"1545_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S2213-8587(17)30089-X","volume":"5","author":"G Giamouzis","year":"2017","unstructured":"Giamouzis G, Butler J. Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes? Lancet Diabetes Endocrinol. 2017;5(5):314\u20135.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1545_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0167-0115(95)00063-H","volume":"58","author":"K Hupe-Sodmann","year":"1995","unstructured":"Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7\u201336) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58(3):149\u201356.","journal-title":"Regul Pept"},{"issue":"9","key":"1545_CR29","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","volume":"48","author":"A Plamboeck","year":"2005","unstructured":"Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48(9):1882\u201390.","journal-title":"Diabetologia"},{"issue":"5","key":"1545_CR30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ejhf.1342","volume":"21","author":"H Nougue","year":"2019","unstructured":"Nougue H, Pezel T, Picard F, Sadoune M, Arrigo M, Beauvais F, et al. Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598\u2013605.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"1545_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0735-1097(97)00185-X","volume":"30","author":"JW Swan","year":"1997","unstructured":"Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30(2):527\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1545_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report from the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. Eur J Heart Fail. 2021;23(3):352\u201380.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01545-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T11:03:18Z","timestamp":1655550198000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01545-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01545-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the appropriate national and institutional regulatory and ethics boards and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MOW has served on advisory boards or lectured for MSD, Lilly, Novo Nordisk and Sanofi, and has organized a professional regional meeting sponsored by Lilly, Rubin Medical, Sanofi, Novartis and Novo Nordisk. BC reports consulting for Amgen, Boehringer Ingelheim, Corvia, Myokardia, Novartis. MV has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Relypsa, and Roche Diagnostics, speaker engagements with Novartis and Roche Diagnostics, and participates on clinical endpoint committees for studies sponsored by Galmed and Novartis. MP reports the following disclosures: Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson, Lilly, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Theravance. MZ reports consulting for Novartis, and is a member of the steering committees for both PARADIGM-HF and PARAGON-HF. JR reports the following disclosures: Consultant Novartis, Aventis, AstraZeneca, Bayer, Myokardia\/BMS. KS reports honoraria from Astrazeneca, Boerhinger-Mannheim, Novartis. ML is a full-time employee of Novartis Pharmaceuticals. SJS has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has served consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards, Eisai, Ionis, Ironwood, Merck, MyoKardia, Novartis, Prothena, Pfizer, Regeneron, Sanofi, Shifamed, Tenax, and United Therapeutics. MAP reports research grant support to institution from Novartis; serves on PARAGON-HF Steering Committee and Study Chair of PARADISE-MI; reports consulting for AstraZeneca, Boehringer Ingelheim and Eli Lilly Alliance, Corvidia, DalCor, GlaxoSmithKline, NHLBI CONNECTs (Master Protocol Committee), Novartis, Novo Nordisk, Peerbridge and Sanofi; and has equity in DalCor and Peerbridge. JJVM reports payments to his employer, Glasgow University, for his work on clinical trials, consulting and other activities: Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GSK, Ionis, KBP Biosciences, Novartis, Pfizer, Theracos, and personal payments: Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Ionis, Lupin, ProAdWise Communications, Sun Pharmaceuticals, Servier. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH\/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta. JCW, RR and AJ report no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}